SGLT2 inhibitor is kidney protective, even if eGFR <30
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- ESC Congress 2024
Disease-modifying effects of finerenone in CKM syndrome
Muthiah Vaduganathan, MD
- ACC.24
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Alexander J. Blood, MD
Ellie Kelepouris, MD
Stephen J. Greene, MD
- Tackling the risk of hyperkalemia through guideline-recommended heart failure therapyThe key role of RAASi therapy in patients with HF
Shelley Zieroth, MD